AAPL339.50-3.44 (-1.00%) ▼|ABBV289.08+6.40 (+2.26%) ▲|ABT102.45-1.61 (-1.55%) ▼|ACN239.12+2.19 (+0.92%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.56+0.53 (+0.29%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.34+1.93 (+0.61%) ▲|BA190.47-0.95 (-0.50%) ▼|BAC50.64+0.25 (+0.50%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.68+4.08 (+0.36%) ▲|BMY61.68+2.85 (+4.84%) ▲|BNY144.25+1.81 (+1.27%) ▲|BRK-B539.82+7.59 (+1.43%) ▲|C122.51+0.82 (+0.67%) ▲|CAT725.24-0.55 (-0.08%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.56+1.73 (+0.87%) ▲|COP145.95+0.71 (+0.49%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.43-0.02 (-0.01%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.75+2.07 (+2.23%) ▲|CVX225.71+1.34 (+0.60%) ▲|DE632.20+5.20 (+0.83%) ▲|DHR224.24-0.19 (-0.08%) ▼|DIS111.67+2.08 (+1.90%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.46-0.08 (-0.05%) ▼|FDX298.76+4.98 (+1.70%) ▲|GD344.44+3.01 (+0.88%) ▲|GE299.87-11.41 (-3.67%) ▼|GEV890.33-18.11 (-1.99%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.09-5.66 (-6.84%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.81+9.03 (+1.03%) ▲|HD315.11+5.23 (+1.69%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM241.92+5.53 (+2.34%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.36+5.57 (+2.19%) ▲|JPM335.26+1.73 (+0.52%) ▲|KO93.49+0.07 (+0.07%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,283.66+43.32 (+3.49%) ▲|LMT548.71+0.48 (+0.09%) ▲|LOW198.53+2.61 (+1.33%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.42+4.02 (+0.65%) ▲|MCD246.52+3.85 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.63+1.86 (+2.01%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.37+9.36 (+5.78%) ▲|MO74.64+0.55 (+0.74%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.40+1.93 (+1.08%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.86+0.69 (+0.88%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.88+0.67 (+1.80%) ▲|NOW149.54+4.18 (+2.88%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.14+1.55 (+1.20%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.11+0.67 (+2.28%) ▲|PG159.32+1.63 (+1.03%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.90-1.15 (-0.57%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.37+7.99 (+1.18%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|AAPL339.50-3.44 (-1.00%) ▼|ABBV289.08+6.40 (+2.26%) ▲|ABT102.45-1.61 (-1.55%) ▼|ACN239.12+2.19 (+0.92%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.56+0.53 (+0.29%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.34+1.93 (+0.61%) ▲|BA190.47-0.95 (-0.50%) ▼|BAC50.64+0.25 (+0.50%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.68+4.08 (+0.36%) ▲|BMY61.68+2.85 (+4.84%) ▲|BNY144.25+1.81 (+1.27%) ▲|BRK-B539.82+7.59 (+1.43%) ▲|C122.51+0.82 (+0.67%) ▲|CAT725.24-0.55 (-0.08%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.56+1.73 (+0.87%) ▲|COP145.95+0.71 (+0.49%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.43-0.02 (-0.01%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.75+2.07 (+2.23%) ▲|CVX225.71+1.34 (+0.60%) ▲|DE632.20+5.20 (+0.83%) ▲|DHR224.24-0.19 (-0.08%) ▼|DIS111.67+2.08 (+1.90%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.46-0.08 (-0.05%) ▼|FDX298.76+4.98 (+1.70%) ▲|GD344.44+3.01 (+0.88%) ▲|GE299.87-11.41 (-3.67%) ▼|GEV890.33-18.11 (-1.99%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.09-5.66 (-6.84%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.81+9.03 (+1.03%) ▲|HD315.11+5.23 (+1.69%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM241.92+5.53 (+2.34%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.36+5.57 (+2.19%) ▲|JPM335.26+1.73 (+0.52%) ▲|KO93.49+0.07 (+0.07%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,283.66+43.32 (+3.49%) ▲|LMT548.71+0.48 (+0.09%) ▲|LOW198.53+2.61 (+1.33%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.42+4.02 (+0.65%) ▲|MCD246.52+3.85 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.63+1.86 (+2.01%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.37+9.36 (+5.78%) ▲|MO74.64+0.55 (+0.74%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.40+1.93 (+1.08%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.86+0.69 (+0.88%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.88+0.67 (+1.80%) ▲|NOW149.54+4.18 (+2.88%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.14+1.55 (+1.20%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.11+0.67 (+2.28%) ▲|PG159.32+1.63 (+1.03%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.90-1.15 (-0.57%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.37+7.99 (+1.18%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|
16.4 C
New York
Wednesday, October 21, 2026

Tag: treatment

newsFORsourcecompanycontentinformation1releasesmarket

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR

NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”), of the important September 15, 2025 lead plaintiff deadline.

MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit – captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.) – seeks to represent purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities and charges Rocket Pharmaceuticals and one of Rocket Pharmaceuticals’ top executives with violations of the Securities Exchange Act of 1934. A subsequently filed case is captioned Yankov v. Rocket Pharmaceuticals, Inc., No. 25-cv-13532 (D.N.J.).

LUNDIN GOLD REPORTS SECOND QUARTER 2025 RESULTS

Exceptional operating performance drives record revenues and free cash flow VANCOUVER, BC, Aug. 7, 2025 /CNW/ - Lundin Gold Inc.  (TSX: LUG) (Nasdaq Stockholm: LUG)...

Bluejay Diagnostics Provides Second Quarter Business and Corporate Update

ACTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced financial results for the quarter ended June 30, 2025, and provided an update on its Symphony IL-6 test program and key operational milestones.

CHICAGO RIVER SWIM APPROVED FOR HISTORIC RETURN THIS SEPTEMBER

First Organized Swim in Nearly a Century will Raise Funds for ALS Research and Youth Swimming Lessons WHAT:            Open Water Swim in the Main Stem of...

Sarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion.

Investors can contact the law firm at no cost to learn more about recovering their losses

Post Holdings Reports Results for the Third Quarter of Fiscal Year 2025; Raises Fiscal Year 2025 Outlook

ST. LOUIS, Aug. 7, 2025 /PRNewswire/ -- Post Holdings, Inc. (NYSE:POST), a consumer packaged goods holding company, today reported results for the third fiscal quarter...

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 –

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

- Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 -

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, Aug. 7, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a...

Chain Transfer Agents Market to Hit USD 365 Million by 2031, Driven by Polymer Demand Surge | Valuates Reports

BANGALORE, India, Aug. 7, 2025 /PRNewswire/ -- What is the Market Size of Chain Transfer Agents Market? The global market for Chain Transfer Agents was valued...

Chain Transfer Agents Market to Hit USD 365 Million by 2031, Driven by Polymer Demand Surge | Valuates Reports

BANGALORE, India, Aug. 7, 2025 /PRNewswire/ -- ...

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs)

Armyworms Threaten Texas Lawns: Dr. Green Services Responds to Rapid Outbreak in DFW Area

DALLAS and FORT WORTH, Texas, Aug. 7, 2025 /PRNewswire/ -- Dr. Green Services has issued an urgent alert for homeowners across North Texas as...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatment

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers